Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
About this episode
Dr. Jacob Sands discusses recent developments in TROP2-directed antibody-drug conjugates for lung cancer management.
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. CME information and select publications here .
People in this episode
Host: Dr. Neil Love
Guest: Dr Jacob Sands
Topics covered
- lung cancer
- TROP2-directed antibody-drug conjugates
- cancer management
- medical research
- oncology
Keywords
- lung cancer
- TROP2
- antibody-drug conjugates
- cancer treatment
- oncology
- medical research
Mentioned in this episode
Organizations: Dana-Farber Cancer Institute
Places: Boston, Massachusetts
More episodes of Lung Cancer Update
- EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
- Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
- Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy
- Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
- Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
- HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach
Explore listener stats, chart rankings, contacts and more on the Lung Cancer Update podcast page.